Cancer and hypertension: A potential for crosstalk?

Journal of Hypertension

Volumn 15, Issue 12 II, 1997, Pages 1573-1577

  Hamet, Pavel ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Apoptosis; Cancer; Cell cycle; Hypertension; Telomeres; Therapy

Indexed keywords

CANCER; CANCER RISK; CONFERENCE PAPER; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0031471555     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715120-00058     Document Type: Conference Paper

References (57)

1. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ: Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996, 9:695-699.
2. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, et al.: Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996, 348:493-497.
3. Hamet P: Cancer and hypertension - an unresolved issue. Hypertension 1996, 28:321-325.
4. Dyer AR, Stamler J, Berkson DM, Lindberg HA, Stevens E: High blood-pressure: a risk factor for cancer mortality? Lancet 1975, i: 1051-1056.
5. Raynor WR Jr, Shekelle RB, Rossof AH, Maliza C, Paul O: High blood pressure and 17-year cancer mortality in the Western Electric Health Study. Am J Epidemiol 1981, 113:371-377.
6. Svardsudd K, Tibblin G: Mortality and morbidity during 13.5 years' follow-up in relation to blood pressure. Acta Med Scand 1979, 205:483-492.
7. Khaw KT, Barrett-Connor E: Systolic blood pressure and cancer mortality in an elderly population. Am J Epidemiol 1984, 120: 550-558.
8. Goldbourt U, Holtzman E, Yaari S, Cohen L, Katz L, Neufeld HN: Elevated systolic blood pressure as a predictor of long-term cancer mortality: analysis by site and histologic subtype in 10,000 middle-aged and elderly men. J Natl Cancer Inst 1986, 77:63-70.
9. Buck C, Donner A: Cancer incidence in hypertensives. Cancer 1987, 59:1386-1390.
10. Filipovsky J, Ducimetière P, Darné B, Richard JL: Abdominal body mass distribution and elevated blood pressure are associated with increased risk of death from cardiovascular diseases and cancer in middle-aged men. The results of a 15- to 20-year follow-up in the Paris prospective study 1. Int J Obes Relat Metab Disord 1993, 17:197-203.
11. Wannamethee G, Shaper AG: Blood pressure and cancer in middle-aged British men. Int J Epidemiol 1996, 25:22-31.
12. Grove JS, Nomura A, Serverson RK, Stemmermann GN: The association of blood pressure with cancer incidence in a prospective study. Am J Epidemiol 1991, 134:942-947.
13. Gillis GR, Hole D, Maclean DS, Hawthorne VM, Watt HD, Watkinson G: High blood pressure and cancer? Lancet 1975, ii:612.
14. Hamet P, Richard L, Dam TV, Teiger E, Orlov SN, Gaboury L, et al.: Apoptosis in target organs of hypertension. Hypertension 1995, 26:642-648.
15. Hamet P, Moreau P, Dam TV, Orlov SN, Tea BS, de Blois D, et al.: The time window of apoptosis: a new component in the therapeutic strategy of cardiovascular remodeling. J Hypertens 1996, 74: 656-667.
16. Taylor JO, Cornoni-Huntley J, Curb JD, Manton KG, Ostfeld AM, Scherr P, et al.: Blood pressure and mortality risk in the elderly. Am J Epidemiol 1991, 134:489-501.
17. Maatela J, Aromaa A, Salmi T, Pohja M, Vuento M, Gronroos M: The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Ann Chir Gynaecol 1994, 83:20-24.
18. Inoue M, Okayama A, Fujita M, Enomoto T, Tanizawa O, Ueshima H: A case-control study on risk factors for uterine endometrial cancer in Japan. Jpn J Cancer Res 1994, 85:346-350.
19. Boston Collaborative Drug Surveillance Program: Reserpine and breast cancer: report from the Boston Collaborative Drug Surveillance Program. Lancet 1974, ii:669-671.
20. Heinonen OP, Shapiro S, Tuominen L, Turunen MI: Reserpine use in relation to breast cancer. Lancet 1974, ii:675-677.
21. Armstrong B, Stevens N, Doll R: Retrospective study of the association use of rauwolfia derivative and breast cancer in English women. Lancet 1974, ii:672-675.
22. Feinstein AR: The architecture of clinical research. In Clinical Epidemiology. Edited by Feinstein AR. Philadelphia: WB Saunders; 1985:321-325.
23. Weinmann S, Glass AG, Weiss NS, Psaty BM, Siscovick DS, White E: Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol 1994, 140:792-804.
24. Chow WH, McLaughlin JK, Mandel JS, Wacholder S, Niwa S, Fraumeni JF Jr: Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension. Cancer Epidemiol Biomarkers Prev 1995, 4:327-331.
25. Mellemgaard A, Niwa S, Mehl E, Engholm G, McLaughlin JK, Olsen JH: Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol 1994, 23:923-930.
26. McLaughlin JK, Chow WH, Mandel JS, Mellemgaard A, McCredie M, Lindblad P, et al.: International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer 1995, 63:216-221.
27. Finkle WD, McLaughlin JK, Rasgon SA, Yeoh HH, Low JE: Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control 1994, 4:555-558.
28. Mellemgaard A, Moller H, Olsen JH: Diuretics may increase risk of renal cell carcinoma. Cancer Causes Control 1992, 3:309-312.
29. Hiatt RA, Tolan K, Quesenberry CP Jr: Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). Cancer Causes Control 1994, 5:319-325.
30. Fletcher AE, Beevers DG, Bulpitt CJ, Coles EC, Dollery CT, Ledingham JG, et al.: Cancer mortality and atenolol treatment. BMJ 1993, 306:622-623.
31. Hole DJ, Hawthorne VM, Isles CG, McGhee SM, Robertson JWK, Gillis CR, et al.: Incidence of and mortality from cancer in hypertensive patients. BMJ 1993, 306:609-611.
32. Liaw KL, Linet MS, McLaughlin JK, Yu MC, Schoenberg JB, Lynch CF, et al.: Possible relation between hypertension and cancers of the renal pelvis and ureter. Int J Cancer 1997, 70:265-268.
33. The SOLVD Investigators: Effect of enelapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
34. Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL, et al.: Cancer risk in users of calcium channel blockers. Hypertension 1997, 29:1091-1094.
35. Pawson T: Protein modules and signaling networks. Nature 1995, 373:573-580.
36. Hadrava V, Tremblay J, Hamet P: Abnormalities in growth characteristics of aortic smooth muscle cells in spontaneously hypertensive rats. Hypertension 1989, 13:589-597.
37. Scott-Burden T, Resink TJ, Baur U, Burgin M, Buhler FR: Epidermal growth factor responsiveness in smooth muscle cells from hypertensive and normotensive rats. Hypertension 1989, 13: 295-304.
38. Weinberg RA, Hanahan D: The molecular pathogenesis of cancer. In Molecular Oncology. Edited by Bishop JM, Weinberg RA. New York: Scientific American, Inc.; 1996:179-204.
39. Berns A: Tumorigenesis in transgenic mice: identification and characterization of synergizing oncogenes. J Cell Biochem 1991, 47:130-135.
40. Vaux DL: Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci U S A 1993, 90:786-789.
41. Hamet P, de Blois D, Dam TV, Richard L, Teiger E, Tea BS, et al.: Apoptosis and vascular wall remodeling in hypertension. Can J Physiol Pharmacol 1996, 74:850-861.
42. Anversa P, Palackal T, Sonnenblick EH, Olivetti G, Capasso JM: Hypertensive cardiomyopathy - myocyte nuclei hyperplasia in the mammalian rat heart. J Clin Invest 1990, 85:994-997.
43. Teiger E, Dam TV, Richard L, Wisnewsky C, Tea BS, Gaboury L, et al.: Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996, 97:2891-2897.
44. de Blois D, Tea BS, Dam TV, Tremblay J, Hamet P: Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 1997, 29:340-349.
45. Kondo S, Yin D, Morimura T, Kudo H, Nakatsu S, Takeuchi J: Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells. Br J Cancer 1995, 71:282-289.
46. Kondo S, Yin D, Morimura T, Takeuchi J: Combination therapy with cisplatin and nifedipine inducing apoptosis in multidrug-resistant human glioblastoma cells. J Neurosurg 1995, 82:469-474.
47. Moreau P, Tea BS, Dam TV, Hamet P: Altered balance between cell replication and apoptosis in hearts and kidneys of newborn SHR. Hypertension 1997, 30:720-724.
48. Diez J, Panizo A, Hernandez M, Pardo J: Is the regulation of apoptosis altered in smooth muscle cells of adult spontaneously hypertensive rats? Hypertension 1997, 29:340-349.
49. Hadrava V, Tremblay J, Sekaly RP, Hamet P: Accelerated entry of aortic smooth muscle cells from spontaneously hypertensive rats into the S phase of the cell cycle. Biochem Cell Biol 1992, 70:599-604.
50. Hamet P, Hadrava V, Tremblay J: The mitogenic process and the vascular wall in hypertension. Lett Pharmacol 1991, 5 (suppl):4-8.
51. Bacakova L, Mares V: Cell kinetics of aortic smooth muscle cells in long-term cultures prepared from rats raised under conventional and SPF conditions. Physiol Res 1995, 44:389-398.
52. Aviv A, Aviv H: Reflections on telomeres, growth, aging, and essential hypertension. Hypertension 1997, 29:1067-1072.
53. Kunes J, Pang SC, Cantin M, Genest J, Hamet P: Cardiac and renal hyperplasia in newborn spontaneously hypertensive rats. Clin Sci 1987, 72:271-275.
54. Pang SC, Long C, Poirier M, Tremblay J, Kunes J, Vincent M, et al.: Cardiac and renal hyperplasia in newborn genetically hypertensive rats. J Hypertens 1986, 4 (suppl 3):S119-S122.
55. Harley CB: Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991, 256:271-282.
56. Chang E, Harley CB: Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci U S A 1995, 92:11190-11194.
57. Prowse KR, Greider CW: Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci U S A 1995, 92:4818-4822.